Trial Profile
Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator's Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Volasertib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 11 Jan 2016 Results published in the Journal of Clinical Oncology
- 26 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Nov 2013 Planned end date changed from 1 Nov 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.